Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

BACKGROUND: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) are serious conditions and are being diagnosed at an increased rate. The etiology of these hepatic disorders is not clear but involves insulin resistance and oxidative stress. Remogliflozin etabonate (Remo) is an in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Exp Hepatol
Autors principals: Nakano, Shigeru, Katsuno, Kenji, Isaji, Masayuki, Nagasawa, Tatsuya, Buehrer, Benjamin, Walker, Susan, Wilkison, William O., Cheatham, Bentley
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4632078/
https://ncbi.nlm.nih.gov/pubmed/26628836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2015.02.005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars